TSH Biopharm Corporation Limited (8432.TWO)
TWD 60.7
(-2.72%)
TWD 60.7
(-2.72%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 33.87 Million | 34.35 Million | 68.7 Million | 11.61 Million | 95.82 Million |
| Net Income | 76.09 Million | 81.24 Million | 61.54 Million | 77.23 Million | 85.32 Million |
| Depreciation & Amortization | 22.57 Million | 21.52 Million | 9.78 Million | 9.64 Million | 9.61 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -39.97 Million | -50.85 Million | 23.4 Million | -66.59 Million | -7.45 Million |
| Other non-cash items | -5.91 Million | -2.63 Million | -2.06 Million | -2.21 Million | 8.34 Million |
| Investing Cash Flow | 161.01 Million | 33.4 Million | -10.06 Million | 234.21 Million | -21.31 Million |
| Investments in PPE | -5.55 Million | -18.72 Million | -382 Thousand | -2.37 Million | -2.99 Million |
| Acquisitions | 9.98 Million | - | - | - | - |
| Investment purchases | - | - | -3.47 Million | - | -90.56 Million |
| Sales/Maturities of investments | 167.86 Million | 44.67 Million | -10.8 Million | 229.43 Million | 71.26 Million |
| Other Investing Activities | -7.75 Million | 1.04 Million | -1.75 Million | 739 Thousand | 1.12 Million |
| Financing Cash Flow | -107.17 Million | -89.4 Million | -73.46 Million | -73.33 Million | -66.67 Million |
| Debt repayment | -48.44 Million | -24.67 Million | - | - | -864 Thousand |
| Dividends payments | -61.43 Million | -57.59 Million | -69.11 Million | -69.11 Million | -61.43 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | 9.98 Million | 201 Thousand | - | - | -4.37 Million |
| Accounts receivables | -3.6 Million | - | - | - | -2.16 Million |
| Accounts payables | -5.92 Million | - | - | - | 5.03 Million |
| Inventory | -11 Million | -13.94 Million | 4.68 Million | -18.85 Million | -11.68 Million |
| Other working capital | -25.36 Million | - | - | - | 1.36 Million |
| Cash at beginning of period | 488.9 Million | 510.52 Million | 396.7 Million | 224.21 Million | 216.37 Million |
| Cash at end of period | 576.58 Million | 488.9 Million | 381.88 Million | 396.7 Million | 224.21 Million |
| Capital Expenditure | -5.55 Million | -18.72 Million | -382 Thousand | -2.37 Million | -2.99 Million |
| Effect of forex changes on cash | -31 Thousand | 27 Thousand | - | - | - |
| Net cash flow / Change in cash | 87.68 Million | -21.62 Million | -14.81 Million | 172.48 Million | 7.84 Million |
| Free Cash Flow | 28.31 Million | 15.62 Million | 68.32 Million | 9.23 Million | 92.83 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 25.7 Million | 45.53 Million | 76.09 Million | 17.63 Million | 21.55 Million | 36.76 Million |
| Depreciation & Amortization | 8.03 Million | 5.73 Million | 22.57 Million | 13.86 Million | 2.65 Million | 159 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -10.33 Million | 2.23 Million | -39.97 Million | -11.41 Million | -19.47 Million | -3.2 Million |
| Other non-cash items | -1.64 Million | -604 Thousand | -5.91 Million | -1.41 Million | -928 Thousand | -2.62 Million |
| Investing Cash Flow | -143.5 Million | -86.19 Million | 161.01 Million | -1.56 Million | 6.52 Million | 167.03 Million |
| Investments in PPE | -794 Thousand | -99 Thousand | -5.55 Million | -1.14 Million | -634 Thousand | 581 Thousand |
| Acquisitions | -242.87 Million | - | - | - | - | - |
| Investment purchases | 85.69 Million | - | - | - | -158.76 Million | 158.67 Million |
| Sales/Maturities of investments | 100 Million | -85.69 Million | 167.86 Million | 520 Thousand | 159.6 Million | 14.41 Million |
| Other Investing Activities | 163 Thousand | -404 Thousand | -7.75 Million | -944 Thousand | -147 Thousand | -6.63 Million |
| Financing Cash Flow | -3.8 Million | -1.83 Million | -107.17 Million | -42.38 Million | -62.56 Million | 24.24 Million |
| Debt repayment | -14.31 Million | - | -48.44 Million | - | - | -24.67 Million |
| Dividends payments | - | - | -61.43 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -3.8 Million | - | 9.98 Million | - | - | - |
| Accounts receivables | 23.32 Million | - | - | - | - | - |
| Accounts payables | -33.76 Million | - | - | - | - | - |
| Inventory | -35.14 Million | -9.39 Million | -11 Million | 6.62 Million | -6 Million | -8.27 Million |
| Other working capital | 20.93 Million | - | - | - | - | - |
| Cash at beginning of period | 542.14 Million | 576.58 Million | 488.9 Million | 517.71 Million | 583.83 Million | 450.41 Million |
| Cash at end of period | 411.57 Million | 542.14 Million | 576.58 Million | 576.58 Million | 517.71 Million | 583.83 Million |
| Capital Expenditure | -794 Thousand | -99 Thousand | -5.55 Million | -1.14 Million | -634 Thousand | 581 Thousand |
| Effect of forex changes on cash | 12 Thousand | 31 Thousand | -31 Thousand | -31 Thousand | 49 Thousand | -9000.00 |
| Net cash flow / Change in cash | -130.57 Million | -34.43 Million | 87.68 Million | 58.87 Million | -66.12 Million | 133.42 Million |
| Free Cash Flow | 15.92 Million | 53.46 Million | 28.31 Million | 17.28 Million | -10.72 Million | 27.15 Million |
BIOG
EEGUF
MTO
3422
5230
BBY